Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Colorectal Cancer (CRC)|Pancreatic Cancer|Non-Small Cell Lung Cancer (NSCLC)|Hepatocellular Carcinoma (HCC)|Melanoma|Sarcoma|Ovarian Cancer|Prostate Cancer
DRUG: Botensilimab|DRUG: Balstililmab
This EAP is available for indications where there is reasonable scientific basis for use. Availability will depend on territory eligibility.